Plasma proenkephalin A and incident chronic kidney disease and albuminuria in the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort

Table 4 Association of PENK-A with progressive eGFR decline (greater or equal 30% decline from baseline)^a

	Quartiles of PENK-A
	Q1	Q2	Q3	Q4	Per SD higher	P value⁺
	(OR, 95% CI)	(OR, 95% CI)	(OR, 95% CI)	(OR, 95% CI)	(OR, 95% CI)	P value⁺
Range of PENK-A	< 48	48–58	59–72	> 72
Number of events/Number at Risk (%)
BioMedioR	192/979 (19.6)	189/979 (19.3)	217/979 (22.2)	233/978 (23.8)	831/3915 (21.2)
Weighted	466/1961 (23.8)	462/1957 (23.6)	502/1957 (25.7)	528/1955 (27)	1958/7830 (25)
Model 1^*	Reference	0.95 (0.75, 1.19)	1.06 (0.84, 1.32)	1.09 (0.87, 1.37)	1.04 (0.96, 1.13)	0.38
Model 2^**	Reference	1.08 (0.85, 1.36)	1.26 (1.00, 1.59)	1.34 (1.05, 1.70)	1.10 (1.01, 1.19)	0.03
Model 3^***	Reference	1.08 (0.84, 1.37)	1.28 (1.00, 1.64)	1.32 (1.00, 1.75)	1.12 (1.00, 1.25)	0.05

P for interaction for sex: 0.11
P for interaction for race: 0.49
^aWeighted to parent cohort and excluding participants missing PENK-A
^*Adjusted for age, sex, race
^**Adjusted for Model 1 plus body mass index, current smoking, coronary artery disease, systolic blood pressure, use of antihypertensive meds, diabetes mellitus
^***Adjusted for Model 2 plus baseline eGFR and uACR
⁺ P value for SD higher of PENK-A

ISSN: 1471-2369